ClinicalTrials.gg
Not yet recruitingNCT07940829Updated Nov 17, 2026

A Study of RSS0343 Tablets in Healthy Participants and in Participants With Mild or Moderate Renal Impairment

A Phase 1 interventional study of RSS0343 Tablet in Non-cystic Fibrosis Bronchiectasis, Chronic Sinusitis Without Nasal Polyps and Chronic Obstructive Pulmonary Disease, sponsored by Reistone Biopharma Company Limited. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Reistone Biopharma Company Limited (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 110 open to participants now, 127 under way, 16 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
246th of 288
24 · median 155
Started
2026
with 35 others
Phase 1
29 of 406
5 open now
Primary completion
2027-02
later than 60 of 126 live
Registered
406th of 406
by date

Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 246th largest by planned enrollment of the 288 interventional ones that give a count, is one of 36 that started in 2026, is one of 29 in phase 1, reaches primary completion later than 60 of the 126 other live ones, and was the 406th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

110 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

105 more — sign in →

All 110 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, single-dose, open-label study designed to evaluate the pharmacokinetic (PK) profile of RSS0343 tablets in healthy participants and in participants with mild or moderate renal impairment.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis
  • Chronic Sinusitis Without Nasal Polyps
  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants voluntarily sign the form (ICF), have a full understanding of the purpose and significance of this study, and are willing to comply with the study protocol.
  2. Males or females aged 18 to 65 years (both boundaries inclusive).
  3. Body weight ≥ 50 kg for males and ≥ 45 kg for females; (BMI) = weight (kg) / height² (m²), with BMI within the range of 19 to 28 kg/m² (both boundaries inclusive).
  4. The absolute value of estimated (eGFR) shall be calculated using the Modification of Diet in Renal Disease (MDRD) equation modified for the Chinese population (for the equation and calculation method). Participants with mild renal impairment: absolute eGFR of 60-89 mL/min; participants with moderate renal impairment: absolute eGFR of 30-59 mL/min (boundary values inclusive); healthy participants: absolute eGFR ≥ 90 mL/min and \< 130 mL/min.
  5. Male and female participants of reproductive / and their partners must have no plan for pregnancy or for sperm / oocyte donation within 6 months (female participants) or 3 months (male participants) after the last dose, and must be willing to use highly effective measures. Female participants of childbearing potential must have a negative serum pregnancy test prior to the first dose and must not be breastfeeding.
  6. (For participants with renal impairment, the following additional inclusion criteria must also be met) The participant has been diagnosed with chronic (> 3 months) and stable renal injury (no acute exacerbation due to deterioration of renal function within 1 month prior to screening), and medical records or laboratory reports confirming the diagnosis of renal impairment for more than 3 months must be provided.
  7. (Participants with normal renal function) Physical examination, 12-lead (12-ECG), vital signs, chest imaging, abdominal ultrasonography (color Doppler ultrasound) and laboratory tests at screening and baseline are normal, or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  1. Those who smoked more than 5 cigarettes per day (or used an equivalent amount of other nicotine-containing products) within 3 months prior to screening, or who plan to use any tobacco products during the study.
  2. Regular alcohol drinkers within 6 months prior to screening (i.e., daily alcohol intake exceeding 15 g for females and 25 g for males [5 g of alcohol is equivalent to 150 mL of beer, 50 mL of wine, or approximately 17 mL of low-alcohol liquor], on more than 2 occasions per week) who are unable to abstain from any alcohol-containing products during the study; or those with a positive alcohol breath test at baseline.
  3. Those with a history of drug abuse, illicit drug use, or drug dependence (as determined by interview/medical history), or a positive urine drug screen at baseline.
  4. Blood donation or blood loss of ≥ 200 mL in total within 1 month prior to dosing, or ≥ 400 mL in total within 3 months prior to dosing; receipt of a blood transfusion within 8 weeks prior to dosing; difficult venipuncture, or a physical condition that cannot tolerate intensive blood collection.
  5. Positive test results for surface antigen (HBsAg), virus antibody (anti-HCV), syphilis antibody, or (HIV) antibody.
  6. Suspected allergy / to the product or any of its components, or a history of severe allergy to any drug, food, toxin, or other exposure.
  7. Any surgery within 3 months prior to screening, or incomplete recovery from surgery as judged by the investigator, or any surgery planned during the study period through 1 month after the end of the study.
  8. Participants who refuse to abstain from any methylxanthine-containing beverages or foods (e.g., coffee, tea, cola, chocolate) from 48 hours prior to baseline until the end of the study; who refuse to abstain from any grapefruit-containing beverages or foods from 7 days prior to baseline until the end of the study; or who have special dietary requirements and are unable to comply with the standardized diet provided in the study.
  9. Receipt of any or live-attenuated vaccine within 1 month prior to screening, or a requirement for vaccination with a live vaccine during study participation (including within 30 days after the last dose of the investigational product).
  10. Those who have participated in any clinical trials involving drugs or medical devices within three months prior to signing the form (or within five elimination half-lives of the studied drug, whichever is the longer period), excluding those who participated in other clinical trials but were not administered the drug due to screening failure.

    Exclusion criteria for participants with renal dysfunction:

  11. According to the judgment of the researchers, participants with renal dysfunction who are not suitable to participate in the study (such as those who have undergone kidney transplantation, those with urinary incontinence or anuria).
  12. Those who, in the investigator's judgment, have experienced marked fluctuation or rapid deterioration of renal function within 2 weeks prior to dosing.
  13. Those who have received renal replacement therapy (e.g., hemodialysis) within 3 months prior to screening, or who are expected to receive renal replacement therapy during the study.
  14. Those with underlying diseases contributing to chronic kidney disease (e.g., diabetes mellitus, hypertension) that have been poorly controlled within 3 months prior to screening, as judged by the investigator.
  15. Other than the primary renal disease itself, any history of serious disease, or any medical history and/or abnormal clinical laboratory findings that, in the investigator's opinion, may affect the study results, including but not limited to a history of diseases of the circulatory, endocrine, nervous or digestive systems, or hematologic, immune, psychiatric or metabolic diseases.
  16. Use of any prescription drugs, over-the-counter (OTC) drugs, Chinese patent medicines or dietary supplements, other than those used for the treatment of renal impairment and other concomitant diseases, within 2 weeks prior to administration of the study drug; or use of strong inhibitors or inducers of and/or P-glycoprotein (P-gp) within 2 weeks prior to administration of the study drug.

    Exclusion criteria for participants with normal renal function:

  17. Previous severe primary diseases of important organs, including but not limited to gastrointestinal, respiratory, renal, liver, nervous, hematological, endocrine, tumor, immune, mental or cardiovascular and cerebrovascular diseases.
  18. Use of any medication (including prescription drugs, over-the-counter drugs, herbal medicines, Chinese patent medicines, and dietary supplements) within 4 weeks prior to screening, or still within 5 half-lives of a drug at the time of screening (whichever is longer).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    RSS0343 Tablet Group

    Administration of RSS0343 tablet.

    Drug: RSS0343 Tablet

Interventions

  • DrugRSS0343 Tablet

    RSS0343 tablet, oral.

06

What researchers measure

Primary outcomes

  1. The maximum plasma concentration (Cmax)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  2. The area under the blood drug concentration-time curve from Time 0 to the last quantifiable concentration time (AUC0-t)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  3. The area under the blood drug concentration-time curve from Time 0 to the extrapolated infinite time (AUC0-inf)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

Secondary outcomes

  1. Time to maximum plasma concentration (Tmax)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  2. Terminal half-life (t1/2)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  3. Apparent clearance (CL/F)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  4. Apparent volume of distribution (Vz/F)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  5. Cumulative amount of drug excreted unchanged in urine (Ae)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  6. Fraction of the administered dose excreted unchanged in urine (Fe)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  7. Renal clearance (CLr)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  8. Plasma protein binding (PPB)

    The PK Parameter.

    Time frame: Day 1 - Day 12.

  9. Incidence and severity of adverse events (AEs)

    Safety Parameter.

    Time frame: Day 1 - Day 12.

07

Study locations

1 site
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    • Youhong Hu · Principal investigator
    • Zhanzheng Zhao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Feb 2027, 3 months later.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 3 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 2026
Primary completionEst.
Feb 2027
CompletionEst.
Apr 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940829
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ruifang Guan
Contact
ruifang.guan.rg1@hengrui.com
+86-518-82342973
Hongda Lin
Contact
hongda.lin@hengrui.com
+86-518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion